Clinical characteristics of males with systemic lupus erythematosus (SLE) in an inception cohort of patients in Ghana.
Male
Sub-Saharan Africa
nephritis
systemic lupus erythematosus
Journal
Ghana medical journal
ISSN: 2616-163X
Titre abrégé: Ghana Med J
Pays: Ghana
ID NLM: 0073210
Informations de publication
Date de publication:
Mar 2019
Mar 2019
Historique:
entrez:
30
5
2019
pubmed:
30
5
2019
medline:
18
12
2019
Statut:
ppublish
Résumé
Systemic Lupus Erythematosus (SLE) is said to be rare in Sub-Saharan Africa and even rarer in males worldwide. SLE is mostly considered a disease of women, though men may also be affected, and this may lead to a delay in diagnosis in men. The result is a greater burden of inflammation and subsequent organ damage over time. Data from the medical records of 13 male patients diagnosed with SLE at the Rheumatology Clinic of Korle- Bu Teaching Hospital between January 2014 and January 2017 was retrospectively analyzed. A total of 13 male patients out of a total of 134 SLE patients were included in our analysis. The mean age was 30.62 ± SD 8.47 years (range of 17 to 46 years). All of them (100%) presented with constitutional features. The most common ACR criteria observed was 61.5 % rash, 54.5 % oral ulcers, 92.3% arthritis, 61.5 % serositis and 38.5% renal involvement, 46.2 % CNS involvement. Looking at their serological profile, 91.7 % had a positive antinuclear antibody (ANA). 33.3 % had positive anti-dsDNA and 58.3 % extractable nuclear antigens. The mean duration from onset of symptoms to diagnosis was 21.31 months. Five patients were diagnosed with lupus nephritis, all at the time of diagnosis. There were no mortalities. Male SLE patients in Ghana are comparable to other populations, with arthritis and constitutional features being predominant early features and lupus nephritis being the main early indicator of organ damage. This should warrant aggressive management in male patients. None declared.
Sections du résumé
BACKGROUND
BACKGROUND
Systemic Lupus Erythematosus (SLE) is said to be rare in Sub-Saharan Africa and even rarer in males worldwide. SLE is mostly considered a disease of women, though men may also be affected, and this may lead to a delay in diagnosis in men. The result is a greater burden of inflammation and subsequent organ damage over time.
METHOD
METHODS
Data from the medical records of 13 male patients diagnosed with SLE at the Rheumatology Clinic of Korle- Bu Teaching Hospital between January 2014 and January 2017 was retrospectively analyzed.
RESULTS
RESULTS
A total of 13 male patients out of a total of 134 SLE patients were included in our analysis. The mean age was 30.62 ± SD 8.47 years (range of 17 to 46 years). All of them (100%) presented with constitutional features. The most common ACR criteria observed was 61.5 % rash, 54.5 % oral ulcers, 92.3% arthritis, 61.5 % serositis and 38.5% renal involvement, 46.2 % CNS involvement. Looking at their serological profile, 91.7 % had a positive antinuclear antibody (ANA). 33.3 % had positive anti-dsDNA and 58.3 % extractable nuclear antigens. The mean duration from onset of symptoms to diagnosis was 21.31 months. Five patients were diagnosed with lupus nephritis, all at the time of diagnosis. There were no mortalities.
CONCLUSION
CONCLUSIONS
Male SLE patients in Ghana are comparable to other populations, with arthritis and constitutional features being predominant early features and lupus nephritis being the main early indicator of organ damage. This should warrant aggressive management in male patients.
FUNDING
BACKGROUND
None declared.
Identifiants
pubmed: 31138937
doi: 10.4314/gmj.v53i1.1
pii: jGMJ.v53.i1.pg2
pmc: PMC6527833
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
2-7Déclaration de conflit d'intérêts
Conflict of interest: None declared
Références
J Rheumatol. 2000 Feb;27(2):373-6
pubmed: 10685799
Lupus. 2000;9(4):252-7
pubmed: 10866095
Ann Rheum Dis. 1992 Sep;51(9):1050-2
pubmed: 1417135
N Engl J Med. 2003 Oct 16;349(16):1526-33
pubmed: 14561795
Gend Med. 2004 Aug;1(1):12-7
pubmed: 16115579
Lupus. 2005;14(12):938-46
pubmed: 16425573
J Clin Rheumatol. 2001 Jun;7(3):142-50
pubmed: 17039119
Arthritis Rheum. 2007 Feb;56(2):622-30
pubmed: 17265497
Arthritis Rheum. 2007 Apr;56(4):1251-62
pubmed: 17393454
Arthritis Rheum. 2008 Aug;58(8):2511-7
pubmed: 18668569
Lupus. 2010 Feb;19(2):119-29
pubmed: 19946032
Clin Exp Rheumatol. 1991 Mar-Apr;9(2):206-7
pubmed: 2060166
Acta Paediatr. 2011 Jun;100(6):819-23
pubmed: 21375582
J Rheumatol. 2012 Apr;39(4):759-69
pubmed: 22382348
Lupus. 2012 Sep;21(10):1041-8
pubmed: 22505605
Orphanet J Rare Dis. 2013 Jan 07;8:2
pubmed: 23289717
Rheumatology (Oxford). 2013 Dec;52(12):2108-15
pubmed: 23641038
Clin Pract. 2011 Nov 08;1(4):e103
pubmed: 24765344
Lancet. 2014 Nov 22;384(9957):1878-1888
pubmed: 24881804
Semin Arthritis Rheum. 1989 Feb;18(3):189-97
pubmed: 2648578
Clin Rev Allergy Immunol. 2017 Aug 9;:null
pubmed: 28795307
Clin Rev Allergy Immunol. 2017 Aug 28;:null
pubmed: 28849549
Arch Intern Med. 1982 Oct;142(10):1813-5
pubmed: 7125767
JAMA. 1981 Mar 6;245(9):934-8
pubmed: 7463697
Br J Rheumatol. 1995 Sep;34(9):866-72
pubmed: 7582729
Lupus. 1994 Jun;3(3):181-6
pubmed: 7951303
Medicine (Baltimore). 1996 May;75(3):124-30
pubmed: 8965681
Arthritis Rheum. 1997 Sep;40(9):1725
pubmed: 9324032